Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Verastem Inc (NQ: VSTM ) 3.420 -0.260 (-7.07%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 606,407 Open 3.680 Bid (Size) 3.390 (20) Ask (Size) 3.570 (4) Prev. Close 3.680 Today's Range 3.400 - 3.790 52wk Range 2.600 - 14.22 Shares Outstanding 25,325,551 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session July 12, 2024 Via Benzinga Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics July 12, 2024 From Verastem Oncology Via Business Wire Performance YTD -58.80% -58.80% 1 Month -1.44% -1.44% 3 Month -68.45% -68.45% 6 Month -69.22% -69.22% 1 Year -62.38% -62.38% More News Read More Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 08, 2024 From Verastem Oncology Via Business Wire VSTM Stock Earnings: Verastem Beats EPS for Q1 2024 May 09, 2024 Via InvestorPlace Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes July 01, 2024 From Verastem Oncology Via Business Wire VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the Firm June 10, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM) June 07, 2024 From Kirby McInerney LLP Via Business Wire 7 F-Rated Stocks to Avoid at All Costs in June June 06, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Monday's Intraday Session May 27, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session May 27, 2024 Via Benzinga Crude Oil Rises 1%; Verastem Shares Slide May 24, 2024 Via Benzinga Exposures Fossil Fuels Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session May 24, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session May 24, 2024 Via Benzinga Nasdaq Gains 1%; Intuit Shares Plunge May 24, 2024 Via Benzinga Is the Stock Market Open on Memorial Day 2024? May 24, 2024 Via InvestorPlace 7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split May 24, 2024 Via InvestorPlace NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial May 24, 2024 Via InvestorPlace Topics Intellectual Property Exposures Intellectual Property Why Is Verastem (VSTM) Stock Down 62% Today? May 24, 2024 Via InvestorPlace Dow Surges 50 Points; US Durable Goods Orders Increase In April May 24, 2024 Via Benzinga Topics Stocks Exposures US Equities What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? May 24, 2024 Via Benzinga Exposures Product Safety Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket May 24, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session May 24, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 24, 2024 Via InvestorPlace Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer May 24, 2024 From Verastem Oncology Via Business Wire Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer May 23, 2024 From Verastem Oncology Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
